Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

The predictors of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and evaluate post-progression treatment and outcomes. We retrospectively enrolled 10...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: I-Cheng Lee, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou, Yi-Hsiang Huang
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2022-04-01
Edice:Cancers
Témata:
hepatocellular carcinoma
sorafenib
regorafenib
progression-free survival
overall survival
post-progression survival
On-line přístup:https://www.mdpi.com/2072-6694/14/8/2014
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky